[Home](https://github.com/mm80843/T3.5/blob/main/docs/index.md) >> Class: [Risk](https://github.com/mm80843/T3.5/tree/main/docs/Risk/index.md) >> Individual ID:PBN__Risk_1528 

# __Lack of vaccines and agent-specific drugs__

## Category to which it belongs

* [Limited capacity, high demand, waning effectiveness, distribution difficulties, and access disparities hinder efficient vaccination efforts.](https://github.com/mm80843/T3.5/blob/main/docs/PBNCategory/PBN__PBNCategory_25.md)

## Closest similar item

* [Lack of drugs and vaccines](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1341.md)
* [Lack of vaccine or cure](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1733.md)
* [Lack of medication and vaccines for covid-19](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1483.md)
* [Lack of knowledge about the virus, treatments, and vaccines](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_2879.md)
* [Lack of covid-19 vaccine](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_2277.md)
* [Lack of preexisting immunities](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_2085.md)
* [Vaccine availability, vaccine hesitancy](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_3118.md)
* [Demand for vaccine development](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_423.md)
* [Inadequate vaccine efficacy](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1888.md)
* [Lack of immunity](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_2731.md)

## Description of the risk

Inadequacy of vaccines and agent-specific drugs for respiratory viruses.

## Type of the risk

* [Physical](https://github.com/mm80843/T3.5/blob/main/docs/RiskHealth/PBN__RiskHealth_0.md)

## Is the risk affecting GBN scales

* [No](https://github.com/mm80843/T3.5/blob/main/docs/ISO/PBN__ISO_Scale_0.md)

## Type of impact of the risk (according to ISO37100)

* [Biodiversity and ecosystem services](https://github.com/mm80843/T3.5/blob/main/docs/ISO/PBN__ISO_Purpose_4.md)

## Type of purpose of the risk (according to ISO37100)

* [Attractiveness](https://github.com/mm80843/T3.5/blob/main/docs/ISO/PBN__ISO_Impact_9.md)

## Mitigations of this risk

* [Investment in research and development for vaccines and agent-specific drugs.](https://github.com/mm80843/T3.5/blob/main/docs/Mitigation/PBN__Mitigation_2066.md)

## Name of the risk

Limited prevention and treatment options during viral epidemics.

## Stakeholders who can mitigate this risk

* [Pharmaceutical companies](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_124.md)
* [Government research institutions](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_991.md)

## Articles mentionning the risk

* [Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review](https://github.com/mm80843/T3.5/blob/main/docs/Article/PBN__Article_22.md)

## People affected by this risk

* [Healthcare workers](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_68.md)
* [General population](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_9.md)

## Technologies linked to the risk

* [Vaccine development](https://github.com/mm80843/T3.5/blob/main/docs/Technology/PBN__Technology_835.md)
* [Antiviral drug research](https://github.com/mm80843/T3.5/blob/main/docs/Technology/PBN__Technology_836.md)

## Property: has_RiskType

* [Technological](https://github.com/mm80843/T3.5/blob/main/docs/RiskType/PBN__RiskType_5.md)

